| US 7,592,145 B2 | ||
| Pin 1 as a marker for prostate cancer | ||
| Lere Bao, Newton, Mass. (US); and Da Gong Wang, Chestnut Hill, Mass. (US) | ||
| Assigned to Pintex Pharmaceuticals, Inc., Watertown, Mass. (US) | ||
| Filed on Jun. 05, 2006, as Appl. No. 11/446,790. | ||
| Application 11/446790 is a continuation of application No. 10/071521, filed on Feb. 08, 2002, abandoned. | ||
| Claims priority of provisional application 60/267552, filed on Feb. 09, 2001. | ||
| Claims priority of provisional application 60/347546, filed on Jan. 10, 2002. | ||
| Prior Publication US 2006/0216764 A1, Sep. 28, 2006 | ||
| Int. Cl. G01N 33/53 (2006.01) | ||
| U.S. Cl. 435—7.1 [530/350; 530/387.1] | 8 Claims |
| 1. A method of determining the likelihood of prostate cancer recurrence in a subject comprising,
providing a biological sample from the subject comprising prostate cancer cells characterized as having a Gleason score of
6 to 7; and
determining the percentage of prostate cancer cells expressing detectable levels of Pin1 polypeptide in the sample by detecting
the binding of an antibody that specifically binds to a Pin1 polypeptide consisting of the amino acid sequence set forth in
SEQ ID NO: 1, or an antigen binding fragment thereof,
wherein the percentage of prostate cancer cells in the sample positive for antibody binding is indicative of the likelihood
of prostate cancer recurrence in the subject.
|